Cargando…
PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy
Tyrosine kinase inhibitors (TKIs) bring significant benefits for patients with cancers harboring epidermal growth factor receptor (EGFR) mutations. However, after treatment for a certain period, most patients ultimately acquire resistance. Numerous studies indicated that PI3K has an important role i...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678642/ https://www.ncbi.nlm.nih.gov/pubmed/33235618 http://dx.doi.org/10.3892/etm.2020.9441 |